Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Shire to Buy Baxalta for $32 Billion
January 11, 2016.
Shire announced today that it has entered into an agreement to acquire Baxalta under a cash and stock deal valued at $45.57 per share, or approximately $32 billion.
The combination of Baxalta and Shire would reportedly create "the number-one rare diseases platform in revenue and pipeline depth", with best-in-class products in each of the following franchises: hematology, immunology, neuroscience, lysosomal storage diseases, gastrointestinal/endocrine, and hereditary angioedema (HAE).
Shire CEO Flemming Ornskov said that the expanded portfolio "will drive our growth to over $20 billion in anticipated annual revenues by 2020."
Recent Videos
Related Content
